Accessibility Menu
 
Sino Biopharmaceutical logo

Sino Biopharmaceutical

(OTC) SBMFF

Current Price$0.76
Market Cap$13.57B
Since IPO (2010)+112%
5 Year-22%
1 Year+70%
1 Month-10%

Sino Biopharmaceutical Financials at a Glance

Market Cap

$13.57B

Revenue (TTM)

$30.57B

Net Income (TTM)

$3.87B

EPS (TTM)

$0.02

P/E Ratio

41.91

Dividend

$0.01

Beta (Volatility)

0.11 (Low)

Price

$0.76

Volume

450

Open

$0.76

Previous Close

$0.76

Daily Range

$0.76 - $0.76

52-Week Range

$0.47 - $1.24

SBMFF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sino Biopharmaceutical

Industry

Pharmaceuticals

Employees

21,435

CEO

S Y Tse

Headquarters

Wan Chai, HK

SBMFF Financials

Key Financial Metrics (TTM)

Gross Margin

82%

Operating Margin

21%

Net Income Margin

15%

Return on Equity

7%

Return on Capital

10%

Return on Assets

5%

Earnings Yield

2.39%

Dividend Yield

0.02%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.57B

Shares Outstanding

17.89B

Volume

450

Short Interest

0.00%

Avg. Volume

161.161

Financials (TTM)

Gross Profit

$25.45B

Operating Income

$6.64B

EBITDA

$7.79B

Operating Cash Flow

$6.62B

Capital Expenditure

$960.10M

Free Cash Flow

$5.66B

Cash & ST Invst.

$22.56B

Total Debt

$16.08B

Sino Biopharmaceutical Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$8.79B

+10.7%

Gross Profit

$7.25B

+11.2%

Gross Margin

82.47%

N/A

Market Cap

$13.57B

N/A

Market Cap/Employee

$556.47K

N/A

Employees

24,379

N/A

Net Income

$1.69B

+12.3%

EBITDA

$1.97B

-0.3%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Net Cash

$7.87B

+124.6%

Accounts Receivable

$8.29B

+13.5%

Inventory

$2.10B

+14.5%

Long Term Debt

$3.08B

+164.7%

Short Term Debt

$8.87B

+4.2%

Return on Assets

4.85%

N/A

Return on Invested Capital

9.90%

N/A

Free Cash Flow

$1.44B

+8.2%

Operating Cash Flow

$1.58B

+2.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KRTXKaruna Therapeutics, Inc.
$329.83+0.03%
URGNUroGen Pharma Ltd.
$21.57+5.07%
IVAInventiva S.A.
$5.26-4.36%
MDWDMediWound Ltd.
$17.85+0.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$128.06-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.61+0.02%
CRWVCoreWeave
$102.00+0.11%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$6.44-0.05%

Questions About SBMFF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.